SLC5A2 and metabolic dysfunction-associated steatohepatitis: Taken together with our previous report that SPPARMα treatment prevents NASH development by reducing myeloid cell recruitment without reducing hepatic TG content [22], the combination of SPPARMα and SGLT2 inhibitor presents a promising new therapy for NASH.